相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Influence of T Cell-Mediated Immune Surveillance on Somatic Mutation Occurrences in Melanoma
Chongming Jiang et al.
FRONTIERS IN IMMUNOLOGY (2022)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
The role of m6A, m5C and Ψ RNA modifications in cancer: Novel therapeutic opportunities
Paz Nombela et al.
MOLECULAR CANCER (2021)
The association between tumor mutational burden and prognosis is dependent on treatment context
Cristina Valero et al.
NATURE GENETICS (2021)
MDSC: Markers, development, states, and unaddressed complexity
Samarth Hegde et al.
IMMUNITY (2021)
The role of the HIF-1α/ALYREF/PKM2 axis in glycolysis and tumorigenesis of bladder cancer
Jing-Zi Wang et al.
CANCER COMMUNICATIONS (2021)
NSUN2 modified by SUMO-2/3 promotes gastric cancer progression and regulates mRNA m5C methylation
Yuanbo Hu et al.
CELL DEATH & DISEASE (2021)
Multi-Omic Analyses of the m5C Regulator ALYREF Reveal Its Essential Roles in Hepatocellular Carcinoma
Chen Xue et al.
FRONTIERS IN ONCOLOGY (2021)
Uncovering the Association Between m5C Regulator-Mediated Methylation Modification Patterns and Tumour Microenvironment Infiltration Characteristics in Hepatocellular Carcinoma
Xinyu Gu et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer
Jiao Hu et al.
THERANOSTICS (2021)
Cancer type-dependent correlations between TP53 mutations and antitumor immunity
Lin Li et al.
DNA REPAIR (2020)
Mapping the epigenetic modifications of DNA and RNA
Lin-Yong Zhao et al.
PROTEIN & CELL (2020)
Risk of hepatocellular carcinoma in individuals without traditional risk factors: development and validation of a novel risk score
Dong Hyun Sinn et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2020)
Overview of distinct 5-methylcytosine profiles of messenger RNA in human hepatocellular carcinoma and paired adjacent non-tumor tissues
Qiyao Zhang et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2020)
Construction of a lipid metabolism-related and immune-associated prognostic signature for hepatocellular carcinoma
Bo Hu et al.
CANCER MEDICINE (2020)
Role of RNA modifications in cancer
Isaia Barbieri et al.
NATURE REVIEWS CANCER (2020)
Hepatocellular Carcinoma
Augusto Villanueva
NEW ENGLAND JOURNAL OF MEDICINE (2019)
PBK overexpression promotes metastasis of hepatocellular carcinoma via activating ETV4-uPAR signaling pathway
Qiu-Xia Yang et al.
CANCER LETTERS (2019)
5-methylcytosine promotes pathogenesis of bladder cancer through stabilizing mRNAs
Xin Chen et al.
NATURE CELL BIOLOGY (2019)
Metascape provides a biologist-oriented resource for the analysis of systems-level datasets
Yingyao Zhou et al.
NATURE COMMUNICATIONS (2019)
A global view of hepatocellular carcinoma: trends, risk, prevention and management
Ju Dong Yang et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
T. A. Chan et al.
ANNALS OF ONCOLOGY (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
CBX2 Regulates Proliferation and Apoptosis via the Phosphorylation of YAP in Hepatocellular Carcinoma
Jiakai Mao et al.
JOURNAL OF CANCER (2019)
Association of Germline Variants in Natural Killer Cells With Tumor Immune Microenvironment Subtypes, Tumor-Infiltrating Lymphocytes, Immunotherapy Response, Clinical Outcomes, and Cancer Risk
Xue Xu et al.
JAMA NETWORK OPEN (2019)
Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: A systematic review and meta-analysis
Richard S. Finn et al.
HEPATOLOGY (2018)
Dynamic transcriptomic m6A decoration: writers, erasers, readers and functions in RNA metabolism
Ying Yang et al.
CELL RESEARCH (2018)
RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2
Mengnuo Chen et al.
HEPATOLOGY (2018)
Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer
Nikolaos Zacharakis et al.
NATURE MEDICINE (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma
Noam Auslander et al.
NATURE MEDICINE (2018)
Monitoring immune-checkpoint blockade: response evaluation and biomarker development
Mizuki Nishino et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma
Martin Lauss et al.
NATURE COMMUNICATIONS (2017)
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Nadeem Riaz et al.
CELL (2017)
5-methylcytosine promotes mRNA export-NSUN2 as the methyltransferase and ALYREF as an m5C reader
Xin Yang et al.
CELL RESEARCH (2017)
BMP4 promotes metastasis of hepatocellular carcinoma by an induction of epithelial-mesenchymal transition via upregulating ID2
Shan Zeng et al.
CANCER LETTERS (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC).
Jean H. Hoffman-Censits et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma
Y. -K. Kang et al.
ANNALS OF ONCOLOGY (2015)
The over-expression of survivin enhances the chemotherapeutic efficacy of YM155 in human hepatocellular carcinoma
Hongping Xia et al.
ONCOTARGET (2015)
Influence of tumour micro-environment heterogeneity on therapeutic response
Melissa R. Junttila et al.
NATURE (2013)
Gemcitabine and Docetaxel for Hepatocellular Carcinoma A Phase II North Central Cancer Treatment Group Clinical Trial
Steven R. Alberts et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2012)
Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma
Qian Zhou et al.
BIOCHEMICAL PHARMACOLOGY (2012)
Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression
Mina J. Bissell et al.
NATURE MEDICINE (2011)
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
David A. Barbie et al.
NATURE (2009)
Identification of novel immunohistochemical tumor markers for primary hepatocellular carcinoma; Clathrin heavy chain and formiminotransferase cyclodeaminase
Masanori Seimiya et al.
HEPATOLOGY (2008)
Hepatocellular carcinoma pathogenesis: from genes to environment
Paraskevi A. Farazi et al.
NATURE REVIEWS CANCER (2006)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
分享论文
